学术界倡议“改变阿尔茨海默氏症规则”

来自产业界和学术界的35个合作者联合发出了欧洲预防阿尔茨海默症的倡议（EPAD）。

计时五年的EPAD项目是由欧盟和欧盟制药工业协会设立的创新医药活动的一部分。该计划的目标是帮助疑有阿尔兹海默症患病征兆的人预防罹患此病，比如其生物标志物异常但“可能很少或根本没有疾病或临床症状”的人群。

爱丁堡大学的Craig Ritchie是EPAD项目的协调代理人，他说该项目是全球倡议的一部分，“这将会彻底改变对早期阿尔茨海默氏症患者或无症状阿尔茨海默氏症风险人群的理解和管理。这可能成为一个扭转规则的计划”。

合作者发表声明称“与一些独立研究的制药公司和学术机构相比，共同合作显然具有优势：相关病人的识别和转诊是非常快速的，在相同的试验中一些治疗方案可以被快速测试出来”。

EPAD项目将建立一个在欧洲范围内拥有24000人参与的巨大的创新医药活动项目，其中1500人将被邀请参加一个新的预防阿尔茨海默氏症的测试试验。该试验将在六个国家或地区的30个地点举行，所有试验数据将公布于众。（转化医学网360zhyx.com）

本文系转化医学网原创编译整理，如需转载，请联系info@360zhyx.com。

附原文：

Pharma/academia launch 'game-changer' Alzheimer's project
Some 35 partners from industry and academia have joined forces to launch the European Prevention of Alzheimer’s Dementia initiative.
The five-year EPAD programme is part of the Innovative Medicines Initiative, set up by the European Union and the European Federation of Pharmaceutical Industries and Associations. The goal is the prevention of dementia in people with evidence of the disease, such as biomarker abnormalities, who “still may have little or no complaints or clinical symptoms”.
University of Edinburgh’s Craig Ritchie, EPAD co-coordinator, said the programme is part of a global initiative “that will make a fundamental difference to the understanding and management of Alzheimer’s disease in people with very early or no symptoms at all. This could be a game-changer”.
The partners issued a statement claiming that “in contrast to several pharmaceutical companies and academic institutions pursuing this in isolation, a joint effort clearly has advantages: the identification and referral of the concerned patients is accelerated and several treatment options can be tested rapidly within one same trial”.
EPAD will establish a European-wide register of 24,000 subjects, of which 1,500 will be invited to participate in a trial to test new treatments for prevention of Alzheimer’s dementia. All data from the trial, which will take place at 30 sites within six country/regional areas, will become publically available for analysis.